The growth and transplantability of the carcinosarcoma of walker 256 in the ascitic form

Agostino, Domenico; Cliffton, Eugene E.

doi:10.1007/bf02146964

Cited by 9 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our laboratory, Walker-256 cells, kindly provided by the Laboratory of Cellular Metabolism Physiology (Federal University of Parana, Brazil), have been maintained in the intraperitoneal cavity of Wistar rats (ascitic form) [18] through weekly passages, every 7 days, by aseptic intraperitoneal injection of 1.0 x 10 6 cells per rat. After 7 days of ascitic growth, the peritoneal exudate is withdrawn and subjected to differential centrifugation at 4°C to obtain tumour cells.…”

Section: Methodsmentioning

confidence: 99%

Chronic Glibenclamide Treatment Attenuates Walker-256 Tumour Growth in Prediabetic Obese Rats

Franco

Previate

Machado

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The sulphonylurea glibenclamide (Gli) is widely used in the treatment of type 2 diabetes. In addition to its antidiabetic effects, low incidences of certain types of cancer have been observed in Gli-treated diabetic patients. However, the mechanisms underlying this observation remain unclear. The aim of the present work was to evaluate whether obese adult rats that were chronically treated with an antidiabetic drug, glibenclamide, exhibit resistance to rodent breast carcinoma growth. Methods: Neonatal rats were treated with monosodium L-glutamate (MSG) to induce prediabetes. Control and MSG groups were treated with Gli (2 mg/kg body weight/day) from weaning to 100 days old. After Gli treatment, the control and MSG rats were grafted with Walker-256 tumour cells. After 14 days, grafted rats were euthanized, and tumour weight as well as glucose homeostasis were evaluated. Results: Treatment with Gli normalized tissue insulin sensitivity and glucose tolerance, suppressed fasting hyperinsulinaemia, reduced fat tissue accretion in MSG rats, and attenuated tumour growth by 27% in control and MSG rats. Conclusions: Gli treatment also resulted in a large reduction in the number of PCNA-positive tumour cells. Although treatment did improve the metabolism of pre-diabetic MSG-rats, tumour growth inhibition may be a more direct effect of glibenclamide.

show abstract

Section: Methodsmentioning

confidence: 99%

Chronic Glibenclamide Treatment Attenuates Walker-256 Tumour Growth in Prediabetic Obese Rats

Franco

Previate

Machado

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Outras formas de obtenção das células do tumor de Walker têm sido utilizadas, como a cultura in vitro 1 e a forma ascítica. 2 Após sucessivos implantes, a neoplasia apresentou variações morfológicas, assumindo formas carcinomatosa, sarcomatosa mista e carcinossarcomatosa. 3 Metástase após inoculação do tumor de Walker, por via intramuscular, tem sido observada nos rins, baço, pulmões, fígado, supra-renais, medula-óssea, coração e língua.…”

Section: Introductionunclassified

Um novo modelo de isolamento do tumor de Walker utilizando o gradiente de Ficoll-Hypaque

Silva

Farias

et al. 2006

Acta Cir. Bras.

View full text Add to dashboard Cite

show abstract

Studies of dormant tumor cells

Sugarbaker

Ketcham

Cohen

1971

Cancer

View full text Add to dashboard Cite

An attempt was made to study dormant tumor cells in a syngeneic, immunologic, experimental tumor system. First, however, tumor cell dormancy was redemonstrated in the Walker 256 tumor‐Sprague‐Dawley rat model as it had been described by Fisher and Fisher. Walker 256 tumor‐cell suspensions were injected intraportally in Sprague‐Dawley rats (non‐inbred). Rats receiving subthreshold doses of tumor underwent serial liver massage beginning 4 or 12 weeks after injection. Control (non‐laparotomized) rats were followed 120 days, and livers were tumor‐negative at the time of sacrifice. Rats receiving subthreshold doses of 5 × 103, 2.5 × 104, and 1.25 × 105 cells were massaged four times at 4‐week intervals. In these groups, 85%, 73%, and 92%, respectively, developed liver metastases. An attempt to demonstrate dormant cells in syngeneic Fisher rats using a 3–4 benz(a)pyrene induced sarcoma was not successful. Ninety‐eight animals receiving subthreshold intraportal doses of this tumor serially underwent 6 liver massages at 4‐week intervals. In no instance were “dormant cells” stimulated to gross or microscopically discernible growth. The 3–4 benzpyrene sarcoma was shown to be highly immunogenic in Fisher rats. The Walker 256 tumor was not demonstrated immunogenic in Sprague‐Dawley rats. Possible explanations for these contrasting results are discussed.

show abstract

The growth and transplantability of the carcinosarcoma of walker 256 in the ascitic form

Cited by 9 publications

References 6 publications

Chronic Glibenclamide Treatment Attenuates Walker-256 Tumour Growth in Prediabetic Obese Rats

Chronic Glibenclamide Treatment Attenuates Walker-256 Tumour Growth in Prediabetic Obese Rats

Um novo modelo de isolamento do tumor de Walker utilizando o gradiente de Ficoll-Hypaque

Studies of dormant tumor cells

Contact Info

Product

Resources

About